Stockscreener 앱 받기
14.94
0.20%
-0.03
시간 외 거래:
14.94
Viatris Inc 주식(VTRS)의 최신 뉴스
Is Viatris (VTRS) One of the Best Medical Stocks to Buy Under $30? - Insider Monkey
Vanguard discloses 7.36% stake in Viatris (NASDAQ: VTRS) - Stock Titan
Merz Gets 2 More Months To Block Generic MS Drug - Law360
Viatris (VTRS) Earnings Expected to Grow: Should You Buy? - Yahoo Finance
Viatris Inc. stock rises Wednesday, outperforms market - MarketWatch
Viatris Inc. stock rises Monday, outperforms market - MarketWatch
Trazodone Market Growth Size 2026, Trends, Industry Analysis, - openPR.com
Viatris Inc. (VTRS) Stock Analysis: Exploring Potential Gains With A 7.76% Upside - DirectorsTalk Interviews
Does Xanax XR Recall Over Dissolution Issues Change The Bull Case For Viatris (VTRS)? - simplywall.st
Viatris gains as UBS upgrades to buy on outlook and pipeline - MSN
Viatris shares break six-session winning streak - MSN
Viatris Inc. stock rises Friday, outperforms market - MSN
VTRS Price Today: Viatris Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
Viatris Inc. stock falls Friday, underperforms market - MarketWatch
Discipline and Rules-Based Execution in VTRS Response - Stock Traders Daily
VTRS News | VIATRIS INC (NASDAQ:VTRS) - ChartMill
Viatris in charts: Generic sales drop 16% in Q1; revenue from Developed Markets falls 13% - MSN
Viatris Inc. stock rises Thursday, outperforms market - MarketWatch
FDA Issues Nationwide Recall of ‘Extended Release’ Xanax for Anxiety - Healthline
Taking Xanax XR? FDA Recalls Batch Over Effectiveness Concerns - AOL.com
Viatris' Q1 2026 Earnings: What to Expect - Yahoo Finance
Viatris Inc. stock falls Wednesday, underperforms market - MarketWatch
Is Viatris Inc (VTRS) Set to Underperform? Analyzing the Factors Limiting Growth - GuruFocus
Viatris Inc. (VTRS) Stock Analysis: Navigating Challenges With A 7.10% Potential Upside - DirectorsTalk Interviews
Transdermal Skin Patches Market 2026- 2033 Overview: Share, - openPR.com
FDA Lists Xanax Recall. Here’s What You Need To Know - Forbes
Natera, UFP Technologies, Mettler-Toledo, and Viatris Shares Are Soaring, What You Need To Know - Yahoo Finance
Is Viatris Inc (VTRS) Overvalued After 4.7% Rally? GF Value Says - GuruFocus
Xanax recalled nationwide due to potential issue with quality, efficacy - The National News Desk
Popular anxiety medication recalled nationwide after FDA warning - NewsNation
Xanax XR recalled after discovery that tablets may fail to release medication properly - Fox Business
Viatris (VTRS) CCO nets 107,135 shares after RSU and DEU vesting - Stock Titan
Why the Xanax recall may not impact your prescription - The Hill
Popular Prescription Medication Xanax Is Being Recalled Nationwide - AOL.com
Xanax from West Virginia-based company recalled nationwide. What you need to know - Los Angeles Times
Xanax bottles recalled nationwide over dissolution issues - WCVB
Popular anxiety Xanax drug recalled nationwide: How to check if your prescription is included - nypost.com
Xanax, popular anxiety medication, recalled: What to know - FOX 13 Tampa Bay
Popular anxiety drug Xanax recalled nationwide: What to know - NBC 5 Chicago
Bottles of Xanax, a popular anxiety drug, recalled nationwide. Here’s why - KFOR.com
Popular anxiety prescription recalled nationwide - WJHL
Bottles of Xanax recalled nationwide. Here’s why - CBS 42
Viatris Ophthalmology Data At ASCRS Puts Valuation And Dividend In Focus - Sahm
Viatris to Report First Quarter 2026 Financial Results on May 7, 2026 - Lelezard
FDA Recalls and Warnings: Potentially Contaminated Cough Drops and Eye Drops, Subpotent Thyroid Medications & More - MedShadow Foundation
Behavioral Patterns of VTRS and Institutional Flows - Stock Traders Daily
0.93%
0.66%
자본화:
|
볼륨(24시간):